603707 健友股份
已收盘 09-03 15:00:00
资讯
新帖
简况
股市必读：健友股份新发布《健友股份关于子公司获得美国FDA阿达木单抗注射液增加生产场地注册批件的公告》
证券之星 · 09-03 01:12
股市必读：健友股份新发布《健友股份关于子公司获得美国FDA阿达木单抗注射液增加生产场地注册批件的公告》
健友股份：覆盖研发、注册、生产、全球销售的注射剂全产业链一体化出海模式
证券之星 · 09-02 17:12
健友股份：覆盖研发、注册、生产、全球销售的注射剂全产业链一体化出海模式
健友股份（603707）披露子公司获美国FDA阿达木单抗注射液增加生产场地注册批件，9月1日股价上涨5.42%
证券之星 · 09-01 22:07
健友股份（603707）披露子公司获美国FDA阿达木单抗注射液增加生产场地注册批件，9月1日股价上涨5.42%
股市必读：健友股份新发布《健友股份2026年半年度报告摘要》
证券之星 · 08-31
股市必读：健友股份新发布《健友股份2026年半年度报告摘要》
每周股票复盘：健友股份（603707）Q2净利降51.11%
证券之星 · 08-30
每周股票复盘：健友股份（603707）Q2净利降51.11%
健友股份（603707）2026年中报简析：净利润同比下降34.48%
证券之星 · 08-29
健友股份（603707）2026年中报简析：净利润同比下降34.48%
健友股份(603707.SH)发布半年度业绩，归母净利润1.88亿元，同比下降34.48%
智通财经 · 08-27
健友股份(603707.SH)发布半年度业绩，归母净利润1.88亿元，同比下降34.48%
股市必读：健友股份（603707）8月21日董秘有最新回复
证券之星 · 08-24
股市必读：健友股份（603707）8月21日董秘有最新回复
股市必读：健友股份（603707）8月18日董秘有最新回复
证券之星 · 08-19
股市必读：健友股份（603707）8月18日董秘有最新回复
健友股份：Meitheal渠道复用率高且具成本优势
证券之星 · 08-18
健友股份：Meitheal渠道复用率高且具成本优势
健友股份董秘黄锡伟荣获第十二届金麒麟·金牌董秘荣誉
新浪财经 · 08-10
健友股份董秘黄锡伟荣获第十二届金麒麟·金牌董秘荣誉
股市必读：健友股份（603707）8月7日董秘有最新回复
证券之星 · 08-10
股市必读：健友股份（603707）8月7日董秘有最新回复
健友股份：来法莫林注射剂已在美国启动商业化
证券之星 · 08-07
健友股份：来法莫林注射剂已在美国启动商业化
股市必读：健友股份（603707）7月31日董秘有最新回复
证券之星 · 08-03
股市必读：健友股份（603707）7月31日董秘有最新回复
健友股份(603707.SH)：门冬胰岛素注射液获得美国FDA批准
智通财经 · 07-27
健友股份(603707.SH)：门冬胰岛素注射液获得美国FDA批准
股市必读：健友股份（603707）7月24日董秘有最新回复
证券之星 · 07-27
股市必读：健友股份（603707）7月24日董秘有最新回复
健友股份：2025年是公司生物类似药商业化的重要节点
证券之星 · 07-24
健友股份：2025年是公司生物类似药商业化的重要节点
健友股份：FDA对中国厂区现场核查标准持续收紧
证券之星 · 07-22
健友股份：FDA对中国厂区现场核查标准持续收紧
股市必读：健友股份（603707）7月16日董秘有最新回复
证券之星 · 07-17
股市必读：健友股份（603707）7月16日董秘有最新回复
健友股份：公司及管理层严格遵守证券监管法规
证券之星 · 07-16
健友股份：公司及管理层严格遵守证券监管法规
加载更多
公司概况
公司名称：
南京健友生化制药股份有限公司
所属行业：
医药制造业
上市日期：
2017-07-19
主营业务：
南京健友生化制药股份有限公司的主营业务是药物的研发、规模化生产、全球商业化销售并提供一站式无菌注射剂CDMO服务。公司的主要产品是无菌注射剂业务、肝素原料药业务、CDMO业务、生物药创新业务。
发行价格：
7.21
{"stockData":{"symbol":"603707","market":"SH","secType":"STK","nameCN":"健友股份","latestPrice":7.9,"timestamp":1788418800000,"preClose":7.97,"halted":0,"volume":7410090,"delay":0,"changeRate":-0.0088,"floatShares":1616000000,"shares":1616000000,"eps":0.2989,"marketStatus":"已收盘","change":-0.07,"latestTime":"09-03 15:00:00","open":7.91,"high":8.01,"low":7.88,"amount":58643800,"amplitude":0.0163,"askPrice":7.91,"askSize":172,"bidPrice":7.9,"bidSize":527,"shortable":0,"etf":0,"ttmEps":0.2989,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1788485400000},"marketStatusCode":5,"adr":0,"adjPreClose":7.97,"symbolType":"stock","openAndCloseTimeList":[[1788399000000,1788406200000],[1788411600000,1788418800000]],"highLimit":8.77,"lowLimit":7.17,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1615651020,"isCdr":false,"pbRate":1.84,"roa":"--","peRate":26.430244,"roe":"2.69%","epsLYR":0.36,"committee":0.70269,"marketValue":12764000000,"turnoverRate":0.0046,"status":1,"floatMarketCap":12764000000},"requestUrl":"/m/hq/s/603707","defaultTab":"news","newsList":[{"id":"2664843472","title":"股市必读：健友股份新发布《健友股份关于子公司获得美国FDA阿达木单抗注射液增加生产场地注册批件的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2664843472","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664843472?lang=zh_cn&edition=full","pubTime":"2026-09-03 01:12","pubTimestamp":1788369133,"startTime":"0","endTime":"0","summary":"公司公告汇总：子公司获美国FDA批准阿达木单抗注射液增加南京生产场地，BLA号761216，累计研发投入约13,777.78万元。公司公告汇总健友股份关于子公司获得美国FDA阿达木单抗注射液增加生产场地注册批件的公告南京健友生化制药股份有限公司子公司Emerge Bioscience Pte. Ltd.收到美国FDA签发的阿达木单抗注射液增加生产场地的批件，批准在南京健友生化制药股份有限公司场地生产。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090300001501.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0186","BK0046","603707"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664897006","title":"健友股份：覆盖研发、注册、生产、全球销售的注射剂全产业链一体化出海模式","url":"https://stock-news.laohu8.com/highlight/detail?id=2664897006","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664897006?lang=zh_cn&edition=full","pubTime":"2026-09-02 17:12","pubTimestamp":1788340335,"startTime":"0","endTime":"0","summary":"证券之星消息，健友股份09月02日在投资者关系平台上答复投资者关心的问题。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090200030259.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0186","BK0239","603707","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664529758","title":"健友股份（603707）披露子公司获美国FDA阿达木单抗注射液增加生产场地注册批件，9月1日股价上涨5.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2664529758","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664529758?lang=zh_cn&edition=full","pubTime":"2026-09-01 22:07","pubTimestamp":1788271637,"startTime":"0","endTime":"0","summary":"截至2026年9月1日收盘，健友股份报收于8.37元，较前一交易日上涨5.42%，最新总市值为135.23亿元。近日，健友股份发布关于子公司获得美国FDA阿达木单抗注射液增加生产场地注册批件的公告。公告显示，南京健友生化制药股份有限公司子公司Emerge Bioscience Pte. Ltd.收到美国FDA签发的阿达木单抗注射液增加生产场地的批件，批准在南京健友生化制药股份有限公司场地生产。截至目前，公司为此项目投入研发费用约13,777.78万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090100042354.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","603707","BK0239","BK0186"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663042730","title":"股市必读：健友股份新发布《健友股份2026年半年度报告摘要》","url":"https://stock-news.laohu8.com/highlight/detail?id=2663042730","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663042730?lang=zh_cn&edition=full","pubTime":"2026-08-31 03:17","pubTimestamp":1788117429,"startTime":"0","endTime":"0","summary":"健友股份关于更换公司财务负责人的公告南京健友生化制药股份有限公司于2026年8月27日召开第六届董事会第二次会议，审议通过更换财务负责人的议案，同意聘任陈腊梅女士为公司财务负责人，任期至第六届董事会任期届满。健友股份关于召开2026年半年度业绩说明会的公告南京健友生化制药股份有限公司将于2026年9月17日9:00-10:00通过上证路演中心网络互动方式召开2026年半年度业绩说明会，介绍公司经营成果和财务状况。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083100000928.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603707","BK0046","BK0239","BK0186"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663137010","title":"每周股票复盘：健友股份（603707）Q2净利降51.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663137010","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663137010?lang=zh_cn&edition=full","pubTime":"2026-08-30 03:04","pubTimestamp":1788030253,"startTime":"0","endTime":"0","summary":"截至2026年8月28日收盘，健友股份报收于7.81元，较上周的7.96元下跌1.88%。业绩披露要点：2026年第二季度归母净利润9853.88万元，同比下降51.11%。股本股东变化截至2026年6月30日，健友股份股东户数为3.4万户，较3月31日减少1683.0户，减幅4.72%。健友股份于2026年8月27日宣布聘任陈腊梅女士为财务负责人，任期至第六届董事会任期届满。健友股份将于2026年9月17日9:00-10:00通过上证路演中心召开2026年半年度业绩说明会，介绍经营成果和财务状况。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083000001011.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603707","BK0186","BK0046","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663165490","title":"健友股份（603707）2026年中报简析：净利润同比下降34.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663165490","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663165490?lang=zh_cn&edition=full","pubTime":"2026-08-29 06:11","pubTimestamp":1787955095,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期健友股份发布2026年中报。根据财报显示，健友股份净利润同比下降34.48%。截至本报告期末，公司营业总收入19.26亿元，同比下降2.71%，归母净利润1.88亿元，同比下降34.48%。去年的净利率为14.57%，算上全部成本后，公司产品或服务的附加值高。本文数据来源于健友股份2026年中报，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082900010681.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603707"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662708075","title":"健友股份(603707.SH)发布半年度业绩，归母净利润1.88亿元，同比下降34.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662708075","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662708075?lang=zh_cn&edition=full","pubTime":"2026-08-27 18:07","pubTimestamp":1787825233,"startTime":"0","endTime":"0","summary":"智通财经APP讯，健友股份(603707.SH)披露2026年半年度报告，报告期公司实现营业收入19.26亿元，同比下降2.71%;归属于上市公司股东的净利润1.88亿元，同比下降34.48%;归属于上市公司股东的扣除非经常性损益的净利润1.46亿元，同比下降43.75%;基本每股收益0.12元。报告期内，公司制剂业务营收虽实现规模增长，但伴随销量提升，原材料、生产制造等营业成本同步增加;同时，公司加大新产品市场布局，新品推广、市场宣传力度加大导致相关销售费用增长，综合导致本期盈利水平同比回落。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1487079.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"健友股份(603707.SH)发布半年度业绩，归母净利润1.88亿元，同比下降34.48%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["603707"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661245576","title":"股市必读：健友股份（603707）8月21日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2661245576","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661245576?lang=zh_cn&edition=full","pubTime":"2026-08-24 02:24","pubTimestamp":1787509453,"startTime":"0","endTime":"0","summary":"截至2026年8月21日收盘，健友股份报收于7.96元，下跌6.68%，换手率1.75%，成交量28.32万手，成交额2.3亿元。董秘最新回复投资者： 除了美国，公司再不同区域主要卖哪些产品？当日关注点交易信息汇总：8月21日主力资金净流出968.34万元，占总成交额4.22%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082400001157.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","BK0186","603707"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660491171","title":"股市必读：健友股份（603707）8月18日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2660491171","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660491171?lang=zh_cn&edition=full","pubTime":"2026-08-19 02:50","pubTimestamp":1787079019,"startTime":"0","endTime":"0","summary":"截至2026年8月18日收盘，健友股份报收于7.96元，下跌0.87%，换手率0.54%，成交量8.71万手，成交额6967.65万元。董秘最新回复投资者： Meitheal在美国的渠道复用率高吗？当日关注点交易信息汇总：8月18日主力资金净流出194.87万元，占总成交额2.8%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081900001968.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","603707","BK0186"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660669834","title":"健友股份：Meitheal渠道复用率高且具成本优势","url":"https://stock-news.laohu8.com/highlight/detail?id=2660669834","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660669834?lang=zh_cn&edition=full","pubTime":"2026-08-18 17:54","pubTimestamp":1787046849,"startTime":"0","endTime":"0","summary":"健友股份回复：尊敬的投资者，您好，Meitheal已与GPO、医院系统和北美三大批发商建立长期稳定合作，小分子品种可直接进入既有采购体系快速上量，多肽、单抗等大品种则通过进入GPO短名单、与渠道合作开发自有品牌等方式快速准入——白蛋白紫杉醇上市30天完成首单、利拉鲁肽首年销售突破9000万元，都验证了渠道落地的速度。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081800031950.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0186","603707","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658981939","title":"健友股份董秘黄锡伟荣获第十二届金麒麟·金牌董秘荣誉","url":"https://stock-news.laohu8.com/highlight/detail?id=2658981939","media":"新浪财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658981939?lang=zh_cn&edition=full","pubTime":"2026-08-10 16:51","pubTimestamp":1786351860,"startTime":"0","endTime":"0","summary":"登录新浪财经APP 搜索查看更多考评等级专题：专题：第十二届金麒麟·金牌董秘及优秀证代荣誉榜单揭晓！8月10日，新浪财经第十二届金麒麟金牌董秘榜单正式揭晓。健友股份董事会秘书黄锡伟凭借扎实的合规治理能力、成熟的投资者关系运营、长期稳健的资本价值传递表现，荣耀加冕第十二届金麒麟金牌董秘。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/roll/2026-08-10/doc-inimvnpm8143785.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","603707","BK0046","BK0186"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658809608","title":"股市必读：健友股份（603707）8月7日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2658809608","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658809608?lang=zh_cn&edition=full","pubTime":"2026-08-10 02:14","pubTimestamp":1786299252,"startTime":"0","endTime":"0","summary":"截至2026年8月7日收盘，健友股份报收于8.1元，上涨2.02%，换手率0.73%，成交量11.87万手，成交额9496.83万元。董秘最新回复投资者： 创新药板块最近有些起色了，公司之前说的几款创新药产品进展怎么样了？未来，公司将持续推进创新管线研发转化，后续项目有重大进展，公司将及时履行信息披露义务，感谢您的关注。当日关注点交易信息汇总：8月7日主力资金净流出363.16万元，占总成交额3.82%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081000000965.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603707","BK0239","BK0046","BK0186"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657616364","title":"健友股份：来法莫林注射剂已在美国启动商业化","url":"https://stock-news.laohu8.com/highlight/detail?id=2657616364","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657616364?lang=zh_cn&edition=full","pubTime":"2026-08-07 16:39","pubTimestamp":1786091948,"startTime":"0","endTime":"0","summary":"证券之星消息，健友股份08月07日在投资者关系平台上答复投资者关心的问题。未来，公司将持续推进创新管线研发转化，后续项目有重大进展，公司将及时履行信息披露义务，感谢您的关注。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700027944.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603707","BK0186","BK0239","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656134383","title":"股市必读：健友股份（603707）7月31日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2656134383","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656134383?lang=zh_cn&edition=full","pubTime":"2026-08-03 02:15","pubTimestamp":1785694513,"startTime":"0","endTime":"0","summary":"截至2026年7月31日收盘，健友股份报收于8.09元，下跌0.61%，换手率0.62%，成交量10.05万手，成交额8138.13万元。董秘最新回复投资者： 看到公司门冬胰岛素从FDA获批了，后期在美国的销售是主要通过Meitheal公司开展吗？当日关注点交易信息汇总：7月31日主力资金净流出416.54万元，占总成交额5.12%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080300000888.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603707","BK0046","BK0186"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654906570","title":"健友股份(603707.SH)：门冬胰岛素注射液获得美国FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2654906570","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654906570?lang=zh_cn&edition=full","pubTime":"2026-07-27 15:36","pubTimestamp":1785137802,"startTime":"0","endTime":"0","summary":"智通财经APP讯，健友股份(603707.SH)发布公告，公司全资子公司Emerge Bioscience Pte.Ltd.(以下简称“Emerge”)于近日收到美国食品药品监督管理局(以下简称“美国FDA”)签发的门冬胰岛素注射液的BLA批准信(BLA号：761497/Original1)。本次门冬胰岛素注射液获得美国FDA批准，将进一步提升公司产品的国际影响力，丰富公司国际市场产品线，提高公司国际市场竞争力。若后续推进美国市场上市销售，有望对公司经营业绩产生积极影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1472526.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0046","BK4585","LABU","BK4588","603707","BK0186"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654064285","title":"股市必读：健友股份（603707）7月24日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2654064285","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654064285?lang=zh_cn&edition=full","pubTime":"2026-07-27 02:26","pubTimestamp":1785090373,"startTime":"0","endTime":"0","summary":"截至2026年7月24日收盘，健友股份报收于7.55元，下跌4.07%，换手率0.63%，成交量10.22万手，成交额7845.77万元。董秘最新回复投资者： 公司生物类似药和创新药的布局怎么样了？公司将持续加大研发投入，推动生物类似药与创新药业务成为继肝素、无菌注射剂之后新的增长引擎，具体研发进展及商业化节奏以公司定期报告披露为准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072700001155.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","603707","BK0239","BK0186"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653083706","title":"健友股份：2025年是公司生物类似药商业化的重要节点","url":"https://stock-news.laohu8.com/highlight/detail?id=2653083706","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653083706?lang=zh_cn&edition=full","pubTime":"2026-07-24 17:54","pubTimestamp":1784886861,"startTime":"0","endTime":"0","summary":"2025年是公司生物类似药商业化的重要节点：中国首个阿达木单抗生物类似物获得美国FDA批准上市，利拉鲁肽生物类似药也于2025年4月获批，获批后实现较快的销售放量。公司将持续加大研发投入，推动生物类似药与创新药业务成为继肝素、无菌注射剂之后新的增长引擎，具体研发进展及商业化节奏以公司定期报告披露为准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072400031495.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","BK0186","603707"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653536737","title":"健友股份：FDA对中国厂区现场核查标准持续收紧","url":"https://stock-news.laohu8.com/highlight/detail?id=2653536737","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653536737?lang=zh_cn&edition=full","pubTime":"2026-07-22 16:42","pubTimestamp":1784709743,"startTime":"0","endTime":"0","summary":"证券之星消息，健友股份(603707)07月22日在投资者关系平台上答复投资者关心的问题。投资者提问：看新闻最近有好几家药企都收到了FDA监管文件，健友目前有没有类似风险？健友股份回复：尊敬的投资者您好，公司高度关注同业出海企业的监管动态。整体看，FDA对中国厂区的现场核查标准持续收紧，生产质量体系的稳定性已成为出海药企能否顺利获批的核心变量。公司深耕肝素及无菌注射剂领域二十余年，目前拥有12条通过美国FDA审核的注射剂生产线，各产线运行稳定，公司将持续保持对质量体系的高标准投入。感谢您的关注。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072200034111.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603707","BK0186","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652426010","title":"股市必读：健友股份（603707）7月16日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2652426010","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652426010?lang=zh_cn&edition=full","pubTime":"2026-07-17 01:40","pubTimestamp":1784223620,"startTime":"0","endTime":"0","summary":"截至2026年7月16日收盘，健友股份报收于8.28元，上涨3.63%，换手率1.59%，成交量25.64万手，成交额2.09亿元。董秘最新回复投资者： 想问下公司截至提问之日的股东人数。董秘： 投资者您好，相关疑问回复如下：1、公司及管理层严格遵守证券监管法规，不存在配合资金控盘、打压股价等违法违规行为，二级市场股价受宏观、行业、资金情绪等多重因素影响，公司无法左右股价走势。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071700000897.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0186","603707","BK0239","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651196443","title":"健友股份：公司及管理层严格遵守证券监管法规","url":"https://stock-news.laohu8.com/highlight/detail?id=2651196443","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651196443?lang=zh_cn&edition=full","pubTime":"2026-07-16 18:06","pubTimestamp":1784196382,"startTime":"0","endTime":"0","summary":"证券之星消息，健友股份07月16日在投资者关系平台上答复投资者关心的问题。健友股份回复：投资者您好，相关疑问回复如下：1、公司及管理层严格遵守证券监管法规，不存在配合资金控盘、打压股价等违法违规行为，二级市场股价受宏观、行业、资金情绪等多重因素影响，公司无法左右股价走势。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071600031900.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0186","BK0239","BK0046","603707"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1788459907445,"stockEarnings":[{"period":"1week","weight":-0.0413},{"period":"1month","weight":-0.0295},{"period":"3month","weight":-0.0048},{"period":"6month","weight":-0.1743},{"period":"1year","weight":-0.3054},{"period":"ytd","weight":-0.114}],"compareEarnings":[{"period":"1week","weight":-0.0037},{"period":"1month","weight":0.0313},{"period":"3month","weight":-0.0213},{"period":"6month","weight":-0.0442},{"period":"1year","weight":0.0337},{"period":"ytd","weight":-0.0067}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"南京健友生化制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"34010人(较上一季度减少4.72%)","perCapita":"47505股","listingDate":"2017-07-19","address":"江苏省南京市浦口区高新开发区MA010-1号地","registeredCapital":"161565万元","survey":" 南京健友生化制药股份有限公司的主营业务是药物的研发、规模化生产、全球商业化销售并提供一站式无菌注射剂CDMO服务。公司的主要产品是无菌注射剂业务、肝素原料药业务、CDMO业务、生物药创新业务。","listedPrice":7.21},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"健友股份(603707)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供健友股份(603707)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"健友股份,603707,健友股份股票,健友股份股票老虎,健友股份股票老虎国际,健友股份行情,健友股份股票行情,健友股份股价,健友股份股市,健友股份股票价格,健友股份股票交易,健友股份股票购买,健友股份股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"健友股份(603707)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供健友股份(603707)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}